Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Alok A. Khorana

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9509-0998; OpenAlex author ID A5039576853; NIH RePORTER profile ID 8359292. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 8)
Trials
0
Grants
1
Labs led
1
Collaborators
87
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: 2 papers · 2019: 5 papers · 2020: 2 papers · 2021: none · 2022: 1 grant · 2023: none · 2024: none · 2025: 2 papers

Papers 20

  1. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  2. Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma. Last author DOI 10.1016/j.esmogo.2025.100194↗
  3. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. Last author DOI 10.1002/cam4.3269↗
  4. A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic c… Co-author PMID 33042633↗
  5. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2019.06.016↗
  6. A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer. Co-author DOI 10.1159/000495988↗
  7. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Last author DOI 10.1200/jco.18.01489↗
  8. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.19.00946↗
  9. Evaluating Susceptibility to Pancreatic Cancer: ASCO Clinical Practice Provisional Clinical Opinion Summary. Last author DOI 10.1200/jop.18.00629↗
  10. Adjuvant Treatment in Potentially Curable Pancreatic Cancer: Need to Include Tumor Location in the Equation? Last author DOI 10.1097/mpa.0000000000001125↗
  11. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.2018.78.9636↗
  12. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection. Co-author DOI 10.1111/1751-2980.12551↗
  13. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.2017.72.4948↗
  14. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. Co-author DOI 10.1200/jop.2017.023044↗
  15. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.1412↗
  16. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.5553↗
  17. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.5561↗
  18. Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study. Last author DOI 10.1002/cncr.29298↗
  19. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. Last author DOI 10.1093/jnci/dju011↗
  20. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Last author DOI 10.1160/th10-12-0789↗

Grants 1

  1. Novel approaches to improve prediction of cancer-associated thrombosis U01HL143402↗

Closest collaborators

The 25 strongest of 87 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith R. McCrae · 1 shared grant, 2022 · strength 0.66
  2. Davendra P. S. Sohal · 7 shared papers, 2014–2025 · strength 0.61
  3. Matthew H. G. Katz · 5 shared papers, 2016–2025 · strength 0.47
  4. Eileen Mary O'Reilly · 4 shared papers, 2016–2025 · strength 0.37
  5. Anirban Maitra · 4 shared papers, 2016–2025 · strength 0.36
  6. Ramesh K. Ramanathan · 4 shared papers, 2014–2019 · strength 0.27
  7. Elena M. Stoffel · 2 shared papers, 2019 · strength 0.25
  8. William Adrian Hall · 2 shared papers, 2019–2025 · strength 0.23
  9. Karyn A. Goodman · 2 shared papers, 2019–2025 · strength 0.23
  10. Manisha Palta · 2 shared papers, 2019–2025 · strength 0.23
  11. Deepak Vadehra · 1 shared paper, 2025 · strength 0.23
  12. Thejus Jayakrishnan · 1 shared paper, 2025 · strength 0.23
  13. Renuka V. Iyer · 1 shared paper, 2025 · strength 0.23
  14. Christos K Fountzilas · 1 shared paper, 2025 · strength 0.23
  15. Anitra Engebretson · 4 shared papers, 2016–2017 · strength 0.21
  16. Theodore Sunki Hong · 3 shared papers, 2016–2019 · strength 0.21
  17. Herbert J. Zeh · 3 shared papers, 2016–2019 · strength 0.21
  18. Jordan D. Berlin · 3 shared papers, 2016–2019 · strength 0.21
  19. Richard David Schulick · 3 shared papers, 2016–2019 · strength 0.21
  20. Andrew H. Ko · 2 shared papers, 2016–2025 · strength 0.20
  21. Richard Matthew Walsh · 3 shared papers, 2014–2017 · strength 0.19
  22. Smitha Krishnamurthi · 2 shared papers, 2018–2020 · strength 0.16
  23. Christopher H. Crane · 3 shared papers, 2016–2018 · strength 0.16
  24. Steve Walston · 1 shared paper, 2025 · strength 0.15
  25. Cristina R. Ferrone · 1 shared paper, 2025 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.